GlassScriptPhysician profile
Jacob Anderson Mitchell
NPI 1356800742
$4,376.36
in general payments reported to CMS, 2019-2025
35 companies · $1,577 in 2025
The $1,577 reported for 2025 was more than what 93% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $503 · 2023: $1,128 · 2024: $1,167 · 2025: $1,577.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,873.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,873.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $633.83 | 2022-2025 | |
| Lilly USA, LLC | $570.07 | 2022-2025 | Mounjaro, Zepbound, Trulicity |
| Otsuka America Pharmaceutical, INC. | $438.85 | 2022-2025 | Rexulti |
| Astrazeneca Pharmaceuticals LP | $361.68 | 2023-2025 | Airsupra, Farxiga |
| Novo Nordisk INC | $329.52 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Lundbeck LLC | $282.97 | 2022-2025 | Rexulti |
| Axsome Therapeutics, INC. | $265.92 | 2023-2025 | Auvelity, Symbravo |
| Pfizer INC. | $154.36 | 2023-2025 | |
| Ironshore Pharmaceuticals INC. | $123.52 | 2023-2024 | Jornay Pm |
| Sanofi-Aventis U.S. LLC | $112.60 | 2022-2025 | |
| Glaxosmithkline, LLC. | $112.18 | 2023-2024 | Arexvy, Shingrix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $109.39 | 2022-2023 | Tradjenta, Synjardy |
| Amgen INC. | $109.03 | 2022-2025 | Otezla, Repatha, Repatha |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $105.32 | 2023-2025 | Xifaxan |
| Astellas Pharma US INC | $70.15 | 2023-2025 | Veozah |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $65.01 | 2023-2025 | Cologuard Collection Kit |
| Noven Therapeutics, LLC | $63.99 | 2023-2025 | Xelstrym |
| Collegium Pharmaceutical, INC. | $43.87 | 2025 | Jornay Pm |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $43.17 | 2024 | Caplyta |
| Antares Pharma, INC. | $41.84 | 2025 | Xyosted |
| Phathom Pharmaceuticals, INC. | $32.39 | 2025 | Voquezna |
| Ionis Pharmaceuticals, INC. | $31.17 | 2025 | Dawnzera |
| Nevro Corp. | $30.38 | 2023 | Senza |
| Corcept Therapeutics | $26.55 | 2025 | Korlym |
| Esperion Therapeutics, INC. | $24.64 | 2025 | Nexletol |
| Corium, LLC | $23.79 | 2022 | |
| Stryker Corporation | $21.73 | 2025 | Mako |
| Janssen Pharmaceuticals, INC | $21.45 | 2024 | Spravato |
| Actelion Pharmaceuticals US, INC. | $21.01 | 2025 | Uptravi, Opsumit |
| Merck Sharp & Dohme LLC | $20.15 | 2024 | Capvaxive |
| Biohaven Pharmaceutical Holding Company LTD. | $19.32 | 2022 | |
| Indivior INC. | $19.12 | 2025 | Sublocade |
| Tris Pharma INC | $17.84 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $17.55 | 2023 | Trintellix |
| Bardy Diagnostics, INC. | $12.00 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jacob Mitchell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.